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Objective: Obesity and insulin resistance are associated with increased iron stores, but have conﬂicting
effects on ovarian reserve in women with polycystic ovary syndrome (PCOS). Iron-catalyzed oxidative
stress might be detrimental to ovarian tissue and granulosa cell function. In this study we determined
the association between body iron stores, obesity, and ovarian reserve in women with PCOS.
Materials and Methods: One hundred and ﬁfty-six women diagnosed with PCOS according to Rotterdam
criteria and 30 normoweight healthy control women were enrolled in this cross-sectional study. Ovarian
volume, total antral follicle count, and the anti-Müllerian hormone (AMH) level were measured as an
indicator of ovarian reserve.
Results: Ferritin and transferrin-bound iron levels were signiﬁcantly higher in women with PCOS than
normoweight controls. Obese women with PCOS had higher ferritin levels (p ¼ 0.006), but lower AMH
levels (p < 0.0001) than nonobese women with PCOS. Using univariate analysis, the AMH level and mean
ovarian volume were inversely related to the ferritin level, homeostasis model assessment of insulin
resistance, and body mass index in women with PCOS. Body mass index and ferritin level remained
signiﬁcantly correlated with a lower AMH level and reduced ovarian volume, respectively, after
considering other confounding variables.
Conclusion: An elevated ferritin level and obesity were negatively associated with ovarian volume and
the AMH level, respectively, in women with PCOS.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Polycystic ovary syndrome (PCOS) is the most common endo-
crinopathy in women of reproductive age; PCOS is characterized by
chronic anovulation, hyperandrogenism, and polycystic ovaries.
Women with PCOS are known to have a higher prevalence of
obesity [1,2], metabolism-related disorders [3,4], and insulin
resistance, which have been proposed to correlate with oxidative
stress caused by excess body iron stores [5,6].s and Gynecology, National
uth Road, 100, Taipei, Taiwan.
).
bstetrics & Gynecology. PublishedThe accumulated iron in mouse ovaries and boar testes has been
shown to accelerate gonadal damage during the aging process due
to increasing oxidative stress [7,8]. Serum ferritin levels in men and
women with transfusion-dependent thalassemia major correlate
with the presence of hypogonadism due to injuries, not only
involving the hypothalamus and pituitary glands, but also the go-
nads [9e11]; however, the relationship between iron stores and
gonadal function has never been investigated in humans without
hemochromatosis.
Anti-Müllerian hormone (AMH) is a sensitive marker of ovarian
reserve and granulosa cell function [12,13], and is a predictor of
ovarian aging [9,14,15]. Although the reproductive lifespan of
women with PCOS has been reported to be no different to [16] or
longer than normo-ovulatory women [17], there is a more rapidby Elsevier Taiwan LLC. All rights reserved.
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without PCOS [17].
Ferritin is the cellular storage protein for iron and has also been
the most commonly used indicator of body iron stores in epide-
miologic studies [18,19]. Body iron stores and ferritin levels have
been reported to be associated with type 2 diabetes, obesity,
metabolic syndrome, and nonalcoholic steatohepatitis in the gen-
eral population [20e23] and in women with PCOS [5,6]da ﬁnding
likely related to the tissue injury and organ failure caused by iron-
promoted generation of reactive oxygen species.
Factors involved in the process of oxidative stress and the
insulin-signaling pathway may be related to granulosa cell
dysfunction [24,25]. In addition, obese and diabetic women tend to
have an earlier decline of ovarian reserve and an earlier onset of the
menopause [26,27]; however, the relationships between ovarian
morphology, obesity, and metabolic disturbances in women with
PCOS remain controversial [28,29].
We hypothesize that obesity and insulin resistance-related high
ferritin levels in women with PCOS might be associated with
decreased ovarian reserve due to potential oxidative injuries to the
ovary. The aim of this study was to determine the relationships
between obesity, ferritin level, and ovarian reserve in women with
PCOS. The effects of oligomenorrhea and obesity on ferritin levels
were also determined.
Material and Methods
Patients and data collection
One hundred and ﬁfty-six women with PCOS and a chief
complaint of irregular menstrual cycles and/or clinical hyper-
androgenism, and willing to give informed consent, were consec-
utively recruited from the Reproductive Endocrinology Clinic
(National Taiwan University Hospital, Taipei, Taiwan) at their ﬁrst
visit in this cross-sectional study. Thirty healthy normoweight
volunteers with regular ovulatory cycles (mean cycle length < 35
days), < 30 years of age, andwithout signs of clinical or biochemical
hyperandrogenism served as the control group. Control volunteers,
but not PCOS patients, were enrolled by the aid of advertisement.
None of the volunteers had been prescribed medications before
enrollment. This study protocol was approved by the Research
Ethics Committee of the National Taiwan University Hospital, Tai-
pei, Taiwan. Written informed consent was obtained from all of the
volunteers before participation.
The diagnosis of PCOS was based on the Rotterdam criteria, in
which at least two of the following three criteria were met: (1)
oligomenorrhea (< 8 spontaneousmenstrual cycles per year at least
3 years before enrollment) or amenorrhea; (2) biochemical (serum
total testosterone level  0.8 ng/mL) or phenotypic hyper-
androgenism, including hirsutism and alopecia (acne was excluded
due to an inconsistent correlation with hyperandrogenism in the
literature); and (3) polycystic ovaries (> 12 follicles per ovary by
transvaginal ultrasonography or an ovarian volume > 10 mL per
ovary by transabdominal ultrasonographywith a distended bladder
for virginal women). The menstrual pattern data was obtained by
questionnaire according to the patient's personal annotation or
recall. The average of total spontaneous menstrual bleeding events
every year for the continuous 3 years before enrollment was
counted to deﬁne the severity of oligomenorrhea. Women with
amenorrhea were deﬁned as having no spontaneous menstrual
bleeding without medication and receiving less than one induced
menstrual bleeding cycle every year for at least 3 years before
enrollment. All of the study volunteers were enrolled after
excluding other endocrine, organic, and systemic abnormalities,
such as hyperprolactinemia, thyroid dysfunction, Cushing'ssyndrome, congenital adrenal hyperplasia, adrenal tumors, ovarian
tumors, autoimmune diseases, malignancies, central nervous sys-
tem diseases, current use of oral contraceptives, or the use of
medications known to affect the hypothalamic-pituitary-ovarian
axis (antiandrogens, ovulation induction agents, antidiabetic
medications, antiobesity medications, or glucocorticoids). None of
the volunteers received a blood transfusionwithin 6 months before
enrollment.
Overnight fasting blood samples were collected from PCOS pa-
tients with amenorrhea for > 3 months before hormone-induced
withdrawal bleeding, and in the early follicular phase from those
with PCOS who ovulated spontaneously. The blood sample was
discarded if the serum progesterone level was > 2 ng/mL, or the
serum estradiol level was > 150 pg/mL to exclude the possibility of
delayed ovulation. The process for blood sample collection has been
described in detail previously [4,30]. Blood was processed within
30 minutes of collection, and the blood glucose and insulin levels
were determined on the day of sampling. The remaining serum and
plasma were frozen at 70C until assayed.
Obesity was deﬁned as a body mass index (BMI)  27 kg/m2
based on the suggestion for the Asian as Hong Kong Chinese, Sin-
gaporean, and Indonesians [2].
Measurement of the total antral follicle count and mean ovarian
volume
The mean ovarian volume was measured with transvaginal ul-
trasound for women with sexual experience and transabdominal
ultrasound with a distended bladder for virginal women. The total
antral follicle count (AFC) measurement was only performed for
thosewho underwent transvaginal ultrasound examination (n¼ 75
in the PCOS group and n ¼ 12 in the control group). Pelvic ultra-
sound measurements of the total AFC and mean ovarian volume
were obtained according to a standard protocol [31] by one
physician who was blind to the clinical manifestations of the
enrolled volunteers. Brieﬂy, after the longest medial axis of the
ovary had been determined, the second dimension was measured,
and then the probe was rotated 90 to obtain the third dimension.
Ovarian volume was calculated using a suggested simpliﬁed for-
mula (0.5  length  width  thickness) [32]. The mean ovarian
volume was deﬁned as the average ovarian volume based on
bilateral ovarian measurements. With respect to the AFC mea-
surement, each ovary was scanned in longitudinal and transverse
cross-sections from the inner to the outer margins to enumerate
the follicles measuring between 2 mm and 9 mm in diameter. The
total AFC was deﬁned as the sum of the total number of follicles
counted in both ovaries.
Assay methods
The levels of follicle stimulating hormone, luteinizing hormone
(LH), estradiol, progesterone, total testosterone, sex hormone
binding globulin, insulin, and glucose, and the homeostasis model
assessment of insulin resistance (HOMA-IR) were measured and
calculated as described previously [3]. The quantitative insulin
sensitivity check index (QUICKI) was also applied to evaluate in-
sulin resistance in women with PCOS. The serum levels of ferritin
and transferrin-bound iron were measured with a biochemical
autoanalyzer (TBA-2000FR; Toshiba Medical Systems Cooperation,
Japan). Serum AMH levels were assessed, as in our previous studies
[11,31], using a second-generation enzyme immunoassay (Immu-
notech A Bechman Coulter Company, Marseilles, France), according
to the supplier's instructions. The free androgen index was used to
estimate the bioavailable testosterone. The intra- and interassay
coefﬁcients of variation of all assays were < 10%.
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Numeric variables are presented as the median with inter-
quartile range in parentheses analyzed with the Wilcoxon rank-
sum or KruskalleWallis test where appropriate. Categorical vari-
ables are presented as the number with the percentage in paren-
theses, and compared using Chi-square or Fisher's exact test as
indicated. The optimal sample size needed for the current study
was estimated based on our previous study using the correlation
coefﬁcients between AMH and ferritin levels in women with
transfusion-dependent beta-thalassemia [11]. Based on the
assumption of a correlation coefﬁcient of 0.39, an alpha error of
0.05, and a power of 80%, the estimated total sample size was 46.
The sample size of the control group estimation was based on
literature studying on the difference of ferritin levels in women
with and without PCOS [33]. Based on the assumption of ferritin
levels of 56 ng/mL in PCOS and 38 ng/mL in the control group, a
standard deviation of 25 ng/mL, an alpha error of 0.05, and a power
of 80%, the estimated sample size was 33 in each group. The Sha-
piroeWilk test was used to determine whether or not variables
were normally distributed. Logarithmic transformation of variables
was done before further analyses if variables were shown to deviate
from a normal distribution. Spearman rank's correlation co-
efﬁcients were calculated to determine the correlations between all
variables. Multivariate regression models were applied to assess
the associations between obesity, ferritin levels, and the surrogate
indicators of ovarian reserve as the AMH level, mean ovarian vol-
ume, and total AFC after adjustment for the presence of PCOS, the
LH and total testosterone levels, and the HOMA-IR. To avoid the
effects of collinearity, we used the HOMA-IR instead of fasting
glucose and insulin levels, and used the BMI instead of the waist
circumference in the ﬁnal models. Multiple linear regression ana-
lyses with and without dummy variables were applied to test the
trend and associations of increased ferritin levels and the severity
of oligomenorrhea after adjustment for age and BMI. For all ana-
lyses, a p < 0.05 was considered statistically signiﬁcant. All of the
statistical analyses were performed using the personal computer
version of SAS (version 9.1; SAS Institute, Inc., Cary, NC, USA).Results
Among 156 women with PCOS, 50 (32.1%) were obese with a
BMI  27 kg/m2, according to the deﬁnition of obesity for Asian
adults, and 31 (19.9%) were amenorrheic for at least 3 years. The
BMI, waist circumference, fasting insulin and glucose levels,
QUICKI, and HOMA-IR were signiﬁcantly higher in obese than
nonobese women with PCOS. The ferritin levels (p ¼ 0.006) were
signiﬁcantly higher, but the AMH levels (p < 0.0001) were signiﬁ-
cantly lower in obese than nonobese women with PCOS (Table 1).
Ovarian volume, total AFC, and ferritin, transferrin-bound iron, and
AMH levels were signiﬁcantly higher in nonobese women with
PCOS than in control women of similar age (Table 1).
In women with PCOS, the AMH level and mean ovarian volume
had positive associations with sex hormone binding globulin, LH,
QUICKI, and total testosterone levels, but were negatively corre-
lated with BMI, waist circumference, fasting glucose, fasting insu-
lin, ferritin levels, and the HOMA-IR, as shown in Table 2. The total
AFC was positively correlated with the total testosterone level, but
negatively correlated with the waist circumference. Ferritin and
HOMA-IR were also negatively correlated with the total AFC in
women with PCOS; although, the correlation was not statistically
signiﬁcant. The AMH, ovarian volume, and total AFC were still
negatively associated with ferritin levels, but did not reach statis-
tical signiﬁcance, while the fasting glucose levels were negativelycorrelated with ovarian volume (r ¼ 0.488, p ¼ 0.013) and the
total AFC (r ¼ 0.630, p ¼ 0.028).
Multivariate linear regression analyses showed that the total
testosterone level is the major determinant of the AMH level, mean
ovarian volume, and total AFC (Table 3); however, apart from the
total testosterone level, the BMI (b ¼ 0.81, p ¼ 0.003) and ferritin
level (b ¼ 0.12, p ¼ 0.0002) were negatively correlated with the
AMH level and mean ovarian volume, respectively, after adjusting
for all the explanatory variables, including the presence of PCOS,
BMI, LH, ferritin, total testosterone levels, and the HOMA-IR. The
interaction term among all variables was not signiﬁcant in the
linear regression models.
The ferritin level tended to be higher in women with fewer
spontaneous menstrual cycles (Table 4). Multiple linear regression
analyses revealed that women with fewer menstrual cycles tended
to have a higher serum ferritin level than women with more
menstrual cycles (p for trend ¼ 0.009), and this effect persisted
after further adjustment for age and BMI (p for trend ¼ 0.0087).
Discussion
The current study revealed that obese women with PCOS have
higher ferritin levels, but lower AMH levels than nonobese women
with PCOS. The ferritin level and obesity were inversely related to
the AMH level, mean ovarian volume, and total AFC in womenwith
PCOS. The inverse associations between BMI and AMH level and
between ferritin level and mean ovarian volume remained signiﬁ-
cant after adjustment for all the other explanatory factors,
including the presence of PCOS, obesity, insulin resistance, LH level,
and hyperandrogenemia. The ﬁndings of the present study suggest
that increased iron load and the risk of obesity inwomenwith PCOS
are not only associated with a higher degree of insulin resistance
and metabolic disorders, but also related to diminished ovarian
reserve and reduced menstrual period frequency.
Previous studies have demonstrated that an increased ferritin
level andmarked iron deposition on aging gonads in animal models
and human patients with major thalassemia, suggesting an inverse
association between iron overload and hypogonadism [7e11,34].
The current study is the ﬁrst report of an association between the
ferritin level and diminished ovarian reserve inwomenwith mildly
elevated iron stores, which is related to obesity and insulin resis-
tance. Although the relationship between polycystic ovarian
morphology and metabolic disturbances is controversial in women
with PCOS [28,29], we found inverse associations between ovarian
volume, and the AFC and insulin resistance in women with PCOS
when considering the AFC and ovarian volume as continuous var-
iables. These ﬁndings suggest that metabolic disturbance and iron
loading might affect the degree of polycystic ovarian morphology.
AMH has been reported to be a sensitive marker of diminished
ovarian reserve related to aging [13e15]. The AMH level, AFC, and
ovarian volume could be considered as surrogate markers to
represent ovarian reserve. Although the reproductive lifespan of
womenwith PCOS in comparisonwith womenwithout PCOS is still
in dispute [16,17], there is currently no available evidence to sub-
stantiate an earlier onset of menopause in women with PCOS.
However, evidence from other populations of women with PCOS
showed that obesity, insulin resistance, and diabetes might accel-
erate ovarian aging, resulting in early ovarian reserve decline and
menopause [26,27,35,36]. The inverse association among insulin
resistance, obesity, and AMH level has also been previously re-
ported in women without PCOS [36e38]. Dietary restriction
restored the ovarian reserve in an animal study [39], and these
ﬁndings further substantiated the hypothesis that metabolism-
related chronic oxidative stress may lead to gonadal damage. The
above-mentioned evidence further supports the ﬁnding of a lower
Table 1
Comparisons of all demographic variables between nonobese and obese women with polycystic ovary syndrome, and of nonobese women between those with and without
polycystic ovary syndrome.
Nonobese PCOS
(N ¼ 106)
Obese PCOS
(N ¼ 50)
pb Nonobese control
(N ¼ 30)
pc
Age (y) 24 (20e28) 25 (20e31) NS 26 (24e27) NS
BMI (kg/m2) 21.63 (19.74e23.44) 31.01 (29.34e35.08) <0.0001 20.10 (18.62e21.26) 0.006
Waist circumference (cm) 80 (75e84) 100 (95e107) <0.0001 72 (69e76) <0.0001
FSH (mIU/mL) 6.57 (5.55e7.55) 5.65 (5.05e6.11) <0.0001 7.15 (6.10e8.10) NS
LH (mIU/mL) 12.7 (10.0e16.7) 6.44 (4.91e9.47) <0.0001 4.85 (3.40e6.30) <0.0001
E2 (pg/mL) 45.4 (35.0e56.5) 48.5 (39.1e60.0) NS 34.55 (27.5e29.34) 0.0001
Total testosterone (ng/mL) 0.53 (0.42e0.71) 0.54 (0.41e0.79) NS 0.47 (0.35e0.64) 0.067
SHBG (nmol/L) 45.5 (28.6e60.2) 20.5 (16.5e25.9) <0.0001 56.1 (42.7e73.6) 0.013
FAI (%) 4.15 (2.91e7.05) 10.0 (5.79e13.1) <0.0001 2.74 (2.12e4.02) 0.016
Fasting glucose (mg/dL) 80 (77e84) 84 (80e89) 0.0002 84.5 (82e88) 0.002
Fasting insulin (mU/mL) 2.7 (2.0e5.0) 13.8 (8.3e19.9) <0.0001 3.9 (2.0e6.3) NS
HOMA-IR 0.48 (0.38e1.00) 2.89 (1.65e4.16) <0.0001 0.80 (0.43e1.42) 0.025
QUICKI 0.19 (0.17e0.20) 0.14 (0.13e0.15) <0.0001 0.17 (0.16e0.19) 0.025
AMH (pM) 64 (43e83) 37 (19e56) <0.0001 20 (14e26) <0.0001
Mean ovarian volume (mL) 10.8 (8.7e13.2) 9.9 (7.7e12.8) NS 4.13 (3.72e5.69) <0.0001
Total antral follicle counta 54 (37e67) 51 (30e60) NS 10.0 (8e15) <0.0001
Ferritin (ng/mL) 61.6 (34.1e108.0) 91.3 (61.0e176.3) 0.006 27.7 (16.5e44.2) <0.0001
Transferrin-bound iron (mg/dL) 96.5 (74e130) 85.5 (70e108) 0.044 74 (58e96) 0.002
Data are presented as median (interquartile range) or n (%).
AMH ¼ anti-Müllerian hormone; BMI ¼ body mass index; E2 ¼ estradiol; FAI ¼ free androgen index; FSH ¼ follicle-stimulating hormone; HOMA-IR ¼ homeostasis model
assessment of insulin resistance; LH ¼ luteinizing hormone; NS ¼ nonsigniﬁcant; PCOS ¼ polycystic ovary syndrome; QUICKI ¼ quantitative insulin sensitivity check index;
SHBG ¼ sex hormone binding globulin.
a Total antral follicle counts only available in a total of 12 volunteers without polycystic ovary syndrome (PCOS) and of 75 volunteers with PCOS, among women with PCOS,
21 were obese, and 54 were nonobese.
b Comparisons between obese and nonobese women with polycystic ovary syndrome.
c Comparisons between nonobese women with and without polycystic ovary syndrome.
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nonobese women with PCOS in this study. Our ﬁndings are con-
tradictory to previous studies in which polycystic ovary
morphology did not predict the metabolic phenotype [28,29] and
decreased AMH levels were generally accompanied with weight
loss in women with PCOS [40,41]. These discrepant ﬁndings might
be attributed to ethnic differences because these studies were
mostly conducted in Caucasian women who were reported to have
more prominent features of hyperandrogenism than East Asian
women, and androgen is a well-known determinant of polycystic
ovaries in human and animal studies [31,42]. In addition, the
decrease in AMH levels after weight loss is always accompaniedTable 2
Spearman rank correlation analyses of anti-Müllerian hormone levels, mean ovarian volum
women with polycystic ovary syndrome.
All AMH
Median (IQR)a r
Age (y) 24 (20e28.5) 0.048
BMI (kg/m2) 23.42 (20.68e29.00) 0.392
Waist circumference (cm) 93.5 (77.0e95.0) 0.415
FSH (mIU/mL) 6.14 (5.24e7.21) 0.012
LH (mIU/mL) 11.05 (6.75e15.0) 0.366
E2 (pg/mL) 45.9 (35.6e58.5) 0.071
Total testosterone (ng/mL) 0.54 (0.42e0.74) 0.372
SHBG (nmol/L) 31.8 (20.8e52.2) 0.408
FAI (%) 5.79 (3.45e9.94) 0.112
Fasting glucose (mg/dL) 82 (78e85) 0.227
Fasting insulin (mU/mL) 4.4 (2.0e9.6) 0.339
HOMA-IR 0.83 (0.40e2.00) 0.340
QUICKI 0.17 (0.15e0.20) 0.340
Ferritin (ng/mL) 77.0 (37.5e125.2) 0.186
Transferrin-bound iron (mg/dL) 92.0 (72.0e119.5) 0.180
Data are presented as median with interquartile range.
AFC ¼ antral follicle count; AMH ¼ anti-Müllerian hormone; BMI ¼ body mass index; E2
IR¼ homeostasis model assessment of insulin resistance; LH¼ luteinizing hormone; NS¼
rank correlation coefﬁcient; SHBG ¼ sex hormone binding globulin.with a reduction in the androgen level, but independent from the
weight change in obesewomenwith PCOS [41]. The ﬁnding that the
AMH levels did not change in obese women without PCOS and
hyperandrogenism after weight loss [40] and the inverse associa-
tion between ferritin level, obesity, and ovarian reserve after
considering the effect of hyperandrogenemia in women with PCOS
in this study further substantiate this hypothesis.
The serum ferritin level represents the cellular storage of iron.
Unlike transferrin-bound iron that represents the circulating iron
level, ferritin is the most commonly used indicator for body iron
stores in epidemiologic studies [18,19,21]. Recent studies have re-
ported an association between body iron stores and metabolice, and total antral follicle count with each other andwith all explanatory variables in
Mean ovarian volume Total AFC
p r p r p
NS 0.077 NS 0.119 NS
<0.0001 0.213 0.009 0.177 NS
<0.0001 0.220 0.007 0.247 0.032
NS 0.055 NS 0.195 NS
<0.0001 0.198 0.016 0.168 NS
NS 0.050 NS 0.037 NS
<0.0001 0.240 0.003 0.350 0.002
<0.0001 0.202 0.014 0.203 NS
NS 0.014 NS 0.039 NS
0.004 0.198 0.016 0.182 NS
<0.0001 0.229 0.005 0.175 NS
<0.0001 0.220 0.007 0.193 NS
<0.0001 0.220 0.007 0.193 NS
0.020 0.318 <0.0001 0.200 NS
0.024 0.047 NS 0.043 NS
¼ estradiol; FAI ¼ free androgen index; FSH ¼ follicle-stimulating hormone; HOMA-
nonsigniﬁcant; QUICKI¼ quantitative insulin sensitivity check index; r¼ Spearman
Table 3
Multivariate regression models for the association of anti-Müllerian hormone levels, mean ovarian volume, and total antral follicle count with all the explanatory variables in
all women.
logAMH log(Mean ovarian volume) log(Total AFC)
Model Aa Model Bb Model Aa Model Bb Model Aa Model Bb
PCOS 0.89 (<0.0001) 0.84 (<0.0001) 0.97 (<0.0001) 0.97 (<0.0001) 1.62 (<0.0001) 1.66 (<0.0001)
logBMI 0.81 (0.003) 0.68 (0.016) 0.27 (NS) 0.25 (NS) 0.42 (NS) 0.35 (NS)
logLH 0.090 (NS) 0.24 (0.011) 0.068 (NS) 0.007 (NS) 0.068 (NS) 0.014 (NS)
log(total testosterone) 0.60 (<0.0001) d 0.28 (<0.0001) d 0.37 (0.005) d
logHOMA-IR 0.12 (0.027) 0.005 (NS) 0.023 (NS) 0.0004 (NS) 0.007 (NS) 0.002 (NS)
logFerritin 0.024 (NS) 0.010 (NS) 0.12 (0.0002) 0.11 (0.0007) 0.076 (NS) 0.075 (NS)
Adjusted R2 (%) 43.76 34.63 48.29 43.41 62.58 59.09
Data are presented as regression coefﬁcient (b); p values are indicated in parenthesis.
AFC ¼ antral follicle count; AMH ¼ anti-Müllerian hormone; BMI ¼ body mass index; HOMA-IR ¼ homeostasis model assessment of insulin resistance; LH ¼ luteinizing
hormone; NS ¼ means nonsigniﬁcant.
a Covariates of all Model A include the presence of polycystic ovary syndrome, body mass index, luteinizing hormone, total testosterone, homeostasis model assessment of
insulin resistance, and ferritin levels.
b Covariates of all Model B are the same as Model A except total testosterone.
Table 4
Comparisons of age, body mass index, and ferritin levels in women with polycystic ovary syndrome with different severities of oligomenorrhea.
Mild
oligomenorrhea
Modest
oligomenorrhea
Moderate
oligomenorrhea
Severe oligomenorrhea
and/or amenorrheaa
p p for
trend
Average range of interval (d) 35e45 45e90 90e180 >180
Average spontaneous menstrual
cycles/y
> 8 5e8 2e4 1
No. of women with PCOS 25 50 33 48
Age (y) 21 (19e26) 25.5 (21e28) 25 (23e29) 23 (20e28.5) NS NS
BMI (kg/m2) 22.03 (19.22e27.81) 25.35 (21.27e30.44) 22.65 (21.08e25.69) 23.79 (20.42e28.23) NS NS
Ferritin (ng/mL) 40.6 (34.5e84.2) 68.5 (37.9e119.2) 84.5 (30.4e128.0) 95.8 (51.6e167.7) 0.074 0.009
Data are presented as median with interquartile range.
BMI ¼ body mass index; NS ¼ nonsigniﬁcant; PCOS ¼ polycystic ovary syndrome.
a Among 48 volunteers with severe oligomenorrhea, 35 volunteers were deﬁned as amenorrheic at enrollment.
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steatosis, and hypertension in the general population and in
women with PCOS [5,6,19e23]. Iron depletion therapy, together
with phlebotomy to reduce ferritin levels, have been reported to
improve insulin resistance [43], decrease blood pressure, treat fatty
liver, and improve blood glucose control [44,45]. The association
between disordered metabolism and ferritin levels is independent
of the secondary role of ferritin as an obesity-related acute phase
inﬂammatory marker [5,19]. Iron accumulation in the ovary/testes
[7] accompanied with increased oxidative stress have been re-
ported to accelerate follicle aging [34], ovarian tissue injury [46],
reduced sperm count, and testes weight [8]. Taken together, these
ﬁndings suggest that increased iron stores may be associated with
disturbed metabolism and lead to decreased gonadal function in
women with PCOS. The causal relationships between obesity,
elevated ferritin levels, and diminished ovarian volume in women
with PCOS could not be explained by the evidence provided in the
current study; indeed, additional studies are needed to clarify the
effect of obesity on iron metabolism of the ovary. Furthermore, it is
reasonable for us to speculate that obese women with PCOS might
be more vulnerable to high ferritin levels with the decline in
ovarian reserve and potentially earlier onset of menopause, while
further information is needed to determine whether or not this is
so.
It is likely that the severity of oligomenorrhea, as it relates to
high ferritin level in women with PCOS, is probably due to
decreased menstrual blood loss [5] or secondary to other unknown
causes.Womenwith amenorrhea and severe oligomenorrhea are at
a higher risk of obesity in comparison with women who are
eumenorrheic, whether or not hyperandrogenic [47]. Accordingly,it is known that obesity might confound the association between
the ferritin level and severity of oligomenorrhea. We have reported
for the ﬁrst time a signiﬁcant relationship between ferritin levels
and the severity of oligomenorrhea in women with PCOS after
considering a common risk factor (obesity).
There were some limitations in this study. Women with PCOS
are known to have a higher prevalence of obesity, insulin resis-
tance, and augmented higher AMH levels than women without
PCOS [48]. Chinese women with PCOS [49,50] have been reported
to have a higher prevalence of polycystic ovary morphology, but
less severe hyperandrogenism in comparison with women of other
ethnicities [50]. Therefore, the generalizability of the results of the
present study to other populations may be limited. In addition, the
narrow age range of the enrolled volunteers and lack of obese
controls also limit the interpretation of the results in this study.
In the current study, the body iron stores, as represented by the
ferritin level, were signiﬁcantly related to advanced age, obesity,
insulin resistance, diminished ovarian reserve, and severity of oli-
gomenorrhea in women with PCOS. The inverse impact of obesity
and an elevated ferritin level on the AMH level and mean ovarian
volume in women with PCOS persisted after adjustment for the
BMI, LH level, insulin resistance index, and hyperandrogenemia.
These ﬁndings suggest that obesity and elevated iron stores are
associated with reduced ovarian reserve in women with PCOS, and
might potentially imply a rapid decline in ovarian reserve in obese
women with PCOS.
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